HPGDS and liver cancer: In vitro studies indicate that kahweol and cafestol reduce genotoxicity in human liver cancer cells by activating phase II detoxification enzymes, particularly glutathione S-transferase (GST) and UDP-glucuronosyltransferase, while simultaneously inhibiting carcinogen-activating CYP450 enzymes.